Table 3.
Toxicity Analysis for planned endpoints between IMPT and VMAT plans.
| Variables | IMPT (n = 80) | VMAT (n = 80) | p-Value |
|---|---|---|---|
| NG tube placement, No. (%) | 4 (5.0) | 12(15.0) | 0.026 |
| Percentage Body weight loss (SD) | 4.87 (3.94) | 6.21 (4.15) | 0.038 |
| Weight loss over 7%, No. (%) | 24 (32.4) | 41 (54.7) | 0.006 |
| Weight loss over 7% or NG tube during treatment, No. (%) | 25 (32.9) | 46 (57.5) | 0.002 |
| Grade 3 dermatitis with wound care, No. (%) | 28 (35) | 6 (7.5) | <0.000 |
| Grade 3 mucositis, No. (%) | 8 (10.0) | 14 (17.5) | 0.178 |
| Grade 2–4 Xerostomia, No. (%) | 9 (11.3) | 13 (16.3) | 0.358 |
| Emergency Room Visit | 7 (8.8) | 13 (16.3) | 0.151 |
| Unscheduled Hospitalization | 8 (10.0) | 7 (8.8) | 0.786 |
Abbreviations: IMPT—Intensity-modulated proton therapy, VMAT—Volumetric modulated arc therapy, NG—Nasogastric.